Bin Wang

Bin Wang

Auto-generated profile, based on publicly available information

Bin Wang

Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2022 in Hepatology
Verified
Journal Article
Closed access
PDF file
JHJianglong Han
Jianglong Han
BWBin Wang
Bin Wang
WLWenmin Liu
Wenmin Liu
SWShijie Wang
Shijie Wang
RCRuyan Chen
Ruyan Chen
ZFZhenming Fu
Zhenming Fu

22 November 2018 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
BWBin Wang
Bin Wang
KZKai-Liang Zhao
Kai-Liang Zhao
WHWen-Juan Hu
Wen-Juan Hu
TZTeng Zuo
Teng Zuo
YDYou-Ming Ding
You-Ming Ding
Weixing WangWeixing Wang
Weixing Wang

29 October 2020 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
BWBin Wang
Bin Wang
KZKailiang Zhao
Kailiang Zhao
WHWenjuan Hu
Wenjuan Hu
YDYouming Ding
Youming Ding
WWWeixing Wang
Weixing Wang

21 July 2020 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
FXFang Xia
Fang Xia
WZWeibin Zhou
Weibin Zhou
BWBin Wang
Bin Wang
YHYongmei Hu
Yongmei Hu
Background: Fibrocalculous pancreatic diabetes (FCPD), an uncommon form of secondary diabetes, is caused by chronic nonalcoholic calcific pancreatitis and primarily occurs in tropical countries. Objective: To present our first-hand experiences in the diagnosis and management of FCPD in two patients from a non-tropical location. Case report: Two male Chinese patients (29 and 32 years old) presented with poor insulin function, negative islet cell and glutamate decarboxylase antibodies, and no spontaneous ketosis or abdominal pain. A careful clinical assessment was made and the results were correlated with laboratory findings. Abdominal ultrasound and computed tomography scans further revealed pancreatic calcification, calculi, and pancreatic duct dilation. Differential diagnosis confirmed FCPD and excluded the potential misdiagnosis of type 2 diabetes mellitus. FCPD in these patients was managed with insulin and symptomatic treatment with close monitoring. At the time of submission of this report, the first patient was stable at his last follow-up, but the second had been re-hospitalized for worsening symptoms. Conclusion: Early differential diagnosis of FCPD based on clinical examination and biochemical and radiological investigations, in tandem with insulin therapy, can help manage FCPD effectively.

14 July 2026 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
HZHeng Zhang
Heng Zhang
JMJialin Ma
Jialin Ma
M施meng 施
meng 施
LCLiang Chen
Liang Chen
YZYu-Fei Zhang
Yu-Fei Zhang
WZWen‑Yong Zhou
Wen‑Yong Zhou
Despite the promise of immune checkpoint blockade (ICB), only a minority of non-small-cell lung cancer (NSCLC) patients achieve long-term benefits. In this study, we present a single-cell spatial transcriptomic landscape of NSCLC, revealing a previously uncharacterized link between elevated glutathione peroxidase 8 (Gpx8) and resistance to PD-1 blockade. Through CyTOF, CODEX, and ATAC-sequencing analyses, we demonstrate that Gpx8 knockout in both immunocompetent and humanized mouse models suppress tumor growth. This suppression is accompanied by increased infiltration of antitumor T lymphocytes, reduced enrichment of pro-tumorigenic myeloid cells, and the formation of tertiary lymphoid structures (TLS). Mechanistically, Gpx8 inhibits the activity of the RNA-binding protein Celf1(CUGBP Elav-like family member 1) through disulfide bonding between cysteine 79 of Gpx8 and cysteine 177 of Celf1. This interaction stabilizes CCAAT-enhancer-binding protein β (C/EBPβ) mRNA, promotes CSF1 secretion, and drives the recruitment of myeloid-derived suppressor cells (MDSCs) into the tumor microenvironment. Notably, resistance to anti-PD-1 treatment in Gpx8-expressing NSCLCs can be overcome through enforced expression of Celf1, CSF1R blockade, or a mimic peptide designed to disrupt the Gpx8-Celf1 interaction. Furthermore, anti-PD-1 or rCSF1 treatment activates C/EBPβ and upregulates Gpx8 transcription, establishing a Gpx8-C/EBPβ-CSF1 feedback loop that contributes to immune evasion. These findings provide new insights into the role of Gpx8 in modulating the tumor microenvironment and offer a potential framework for enhancing the sensitivity of NSCLC to PD-1 blockade therapy.